Currently available treatments with demonstrated benefits against NAFLD include lipid-lowering agents (statins), insulin-sensitizing agents (e.g., pioglitazone), apical sodium-dependent bile acid transporter (ASBT) inhibitors, and antioxidants (e.g., vitamin E) (Cusi et al., 2016; Ge et al., 2019; Al-Baiaty et al., 2021; Lee et al., 2021). Here, SLC10A2 is linked to metabolic dysfunction-associated steatotic liver disease.